Full Title: Improving Outcomes through Collaboration In Osteosarcoma
Status: Active, Recruiting
Age Range: All ages
Locations: University College London Hospital, Royal Manchester Children's Hospital, Royal National Orthopaedic Hospital, Christie Hospital, Alder Hey Hospital, Addenbrooke's Hospital, Birmingham Children's Hospital, Great North Children’s Hospital, Royal Victoria Infirmary, Freeman Hospital, Nottingham Children's Hospital Queen's medical centre, Nottingham City Hospital, Churchill Hospital, Oxford Nuffield centre, Robert Jones and Agnes Hunt Orthopaedic Hospital, Royal Aberdeen Children's Hospital, Sheffield Children's Hospital, the Beatson, Clatterbridge Cancer Centre, Oxford Children’s Hospital, John Radcliffe Hospital, Royal Orthopaedic Hospital, Children’s Hospital for Wales, Weston Park Hospital
Registry Number: NCT04132895
Osteosarcoma is the most common form of bone sarcoma in children and teenagers and is usually treated with surgery and a standard first line chemotherapy regime called MAP chemotherapy in this group of patients. Osteosarcoma is unusual in that it has a second peak in incidence in older adults over 50 years and a standard treatment for this group of patients has not been established. Unfortunately, in some patients, it does not respond to treatment or returns after treatment and we currently don't know why and how to stop this happening.
ICONIC aims to recruit osteosarcoma patients of any age and from across the UK and Ireland, where clinical data, such as the stage of disease at diagnosis, the treatment the patient receives and their response to treatment. Tissue samples will also be collected from patients, if they agree, which will be analysed by researchers. By linking a patient's clinical data to what is happening inside their tumour samples, it provides researchers with an invaluable opportunity to understand why some patients respond to treatment and some don't and what causes osteosarcoma to spread to other parts of the body.
The study will also look at how patients are diagnosed and quality of life measures both during and after treatment.
The trial is classed as observational at this stage, meaning that it does not include any novel treatments, however, it has been developed as a framework to allow any new, novel treatments to be added as they become available.
The trial has been funded by the Bone Cancer Research Trust.